Biological significance of miR-126 expression in atrial fibrillation and heart failure

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 11, 2015, Pages 983-989

  Wei, X J ^a   Han, M ^a   Yang, F Y ^a   Wei, Guang Chen ^a   Liang, Z G ^a   Yao, H ^a   Ji, C W ^a   Xie, R S ^a   Gong, C L ^a   Tian, Y ^a  

^a Department of Emergency The People s Hospital of Laiwu City   (China)

Author keywords

Atrial fibrillation; Heart failure; Heart function indices; MicroRNA 126; N terminal prohormone brain natriuretic peptide (NT proBNP)

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA 126; TRIACYLGLYCEROL; BRAIN NATRIURETIC PEPTIDE; MICRORNA; MIRN126 MICRORNA, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTERY DIAMETER; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CARDIOTHORACIC RATIO; CARDIOVASCULAR PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; REAL TIME POLYMERASE CHAIN REACTION; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; BLOOD; HEART ATRIUM FUNCTION; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; ATRIAL FUNCTION; BIOMARKERS; FEMALE; HEART FAILURE; HUMANS; LINEAR MODELS; MALE; MICRORNAS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; VENTRICULAR FUNCTION, LEFT;

EID: 84944602916     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20154590     Document Type: Article

References (39)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292, doi: 10.1161/01.cir.0000441139.02102.80.
2. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 2008; 18: 209-216.
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606-619, doi: 10.1161/HHF.0b013e318291329a.
4. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013; 61: 1-117.
5. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med 2014; 127: 963-971.
6. Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M, et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol 2010; 55: 1796-1802, doi: 10.1016/j.jacc.2010.01.023.
7. De Simone G, Devereux RB, Roman MJ, Chinali M, Barac A, Panza JA, et al. Does cardiovascular phenotype explain the association between diabetes and incident heart failure? The Strong Heart Study. Nutr Metab Cardiovasc Dis 2013; 23: 285-291, doi: 10.1016/j.numecd.2011.06.007.
8. Schnabel RB, Rienstra M, Sullivan LM, Sun JX, Moser CB, Levy D, et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 2013; 15: 843-849.
9. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012; 44: 670-675, doi: 10.1038/ng.2261.
10. Skrzynia C, Berg JS, Willis MS, Jensen BC. Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev 2015; 11: 10-17, doi: 10.2174/1573403X09666131117170446.
11. Xiao J, Liang D, Zhang Y, Liu Y, Zhang H, Liu Y, et al. MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol Genomics 2011; 43: 655-664, doi: 10.1152/physiolgenomics.00139.2010.
12. Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat-Hamedani F, Kayvanpour E, et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J 2013; 34: 2812-2822, doi: 10.1093/eurheartj/eht256.
13. Condorelli G, Latronico MV, Dorn GW. microRNAs in heart disease: putative novel therapeutic targets? Eur Heart J 2010; 31: 649-658, doi: 10.1093/eurheartj/ehp573.
14. Olson EN. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med 2014; 6: 239ps3, doi: 10.1126/scitranslmed.3009008.
15. Fic P, Kowalczuk K, Grabarska A, Stepulak A. [MicroRNA-a new diagnostic tool in coronary artery disease and myocardial infarction]. Postepy Hig Med Dosw 2014; 68: 410-418, doi: 10.5604/17322693.1100348.
16. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, et al. MicroRNA-1 and-133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 2011; 6: e28324, doi: 10.1371/journal.pone.0028324.
17. Ishizaki T, Tamiya T, Taniguchi K, Morita R, Kato R, Okamoto F, et al. miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1. Genes Cells 2011; 16: 803-814, doi: 10.1111/gtc.2011.16.issue-7.
18. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739, doi: 10.1016/S0960-9822(02)00809-6.
19. Jiang Y, Wang HY, Cao HM, Wang CY, Zhang L, Wang H, et al. Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci Rep 2014; 4: 5026.
20. Asgeirsdottir SA, van Solingen C, Kurniati NF, Zwiers PJ, Heeringa P, van Meurs M, et al. MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am J Physiol Renal Physiol 2012; 302: F1630-F1639, doi: 10.1152/ajprenal. 00400.2011.
21. Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci 2012; 8: 811-818, doi: 10.7150/ijbs.4439.
22. Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol 2012; 53: 64-72, doi: 10.1016/j.yjmcc.2012.04.003.
23. Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma miRNAs in congestive heart failure. Circ J 2011; 75: 336-340.
24. Jakob P, Doerries C, Briand S, Mocharla P, Krankel N, Besler C, et al. Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 2012; 126: 2962-2975, doi: 10.1161/CIRCULATIONAHA.112.093906.
25. Jons C, Joergensen RM, Hassager C, Gang UJ, Dixen U, Johannesen A, et al. Diastolic dysfunction predicts newonset atrial fibrillation and cardiovascular events in patients with acute myocardial infarction and depressed left ventricular systolic function: a CARISMA substudy. Eur J Echocardiogr 2010; 11: 602-607.
26. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 2007; 93: 476-482, doi: 10.1136/hrt.2006.089656.
27. Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 2012; 45: 575-581, doi: 10.1016/j.clinbiochem.2012.02.009.
28. Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010; 123: 198-204.
29. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008; 103: 1072-1083, doi: 10.1161/CIRCRESAHA.108.183087.
30. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011; 121: 2955-2968, doi: 10.1172/ JCI46315.
31. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 2008; 86: 313-322.
32. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-284, doi: 10.1016/ j.devcel.2008.07.008.
33. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105: 1516-1521, doi: 10.1073/pnas.0707493105.
34. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 2010; 464: 1196-1200, doi: 10.1038/nature08889.
35. Nikolic I, Plate KH, Schmidt MH. EGFL7 meets miRNA-126: an angiogenesis alliance. J Angiogenes Res 2010; 2: 9, doi: 10.1186/2040-2384-2-9.
36. Qiang L, Hong L, Ningfu W, Huaihong C, Jing W. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol 2013; 168: 2082-2088.
37. Hijazi Z,Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61: 2274-2284, doi: 10.1016/ j.jacc.2012.11.082.
38. Cai B, Wang L, Liu J, Shi Y, Guo Y. N-terminal pro-Brain natriuretic peptide as a useful biomarker for monitoring prognosis in patients with cardiac valve replacement. J Clin Lab Anal 2011; 25: 149-155, doi: 10.1002/jcla.v25.3.
39. Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA-126,-145, and-155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 2013; 33: 449-454, doi: 10.1161/ATVBAHA.112.300279.